Company intelligence / Profile preview

Fonseca Biosciences

Conshohocken, Pennsylvania, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Fonseca Biosciences specializes in acquiring and commercializing pharmaceutical and medical products, with a current focus on the US distribution of XTORO (finafloxacin otic suspension) for acute otitis externa. XTORO is FDA approved but has not yet launched; Fonseca has submitted a supplement for marketing approval and expects to begin distribution in mid-2025. Clinical studies show rapid symptom relief and sustained efficacy with a favorable safety profile.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

MerLion Pharmaceuticals GmbH

Beyond the preview

Go deeper on Fonseca Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fonseca Biosciences.

Explore the full profile